|Podcasts|September 30, 2021
Episode 92: Digesting the GI Market
Author(s)Elaine Quilici, Miranda Schmalfuhs
Tom McCourt, CEO of Ironwood Pharmaceuticals, talks about his 30-plus years in the gastrointestinal space, including his experiences bringing top GI medicines Prilosec, Nexium, Entocort, Zelnorm, and Linzess to market.
Advertisement
Tom McCourt, CEO of Ironwood Pharmaceuticals, discusses his extensive background in gastrointestinal drug development, the current landscape of therapies, and what the future may hold for this space.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12
2
Agentic AI and the Future of Commercial Excellence in Life Sciences
3
FDA Expands Approval for Arexvy for Adult Patients Aged 18-49
4
What is Shadow AI and How is it Impacting Pharma Companies?
5